Table 1.
Baseline Characteristics.
| Variable | HTN (n= 67 ) (±SD) | Control (n= 45) (±SD) | P value |
|---|---|---|---|
| Age (Yrs) | 55 (12.4) | 41 (12.6) | <0.001 |
| Age, Range (Yrs) | 26–76 | 20–69 | |
| % Females | 46.3 | 53.3 | NS |
| % Caucasians | 55.2 | 67.4 | NS |
| SBP (mmHg) | 144 (16) | 118 (13) | <0.001 |
| DBP (mmHg) | 88 (12) | 74 (11) | <0.001 |
| HR (/min) | 68 (12) | 72 (12) | 0.047 |
| Duration of HTN (Yrs) | 16.7(10) | 0 | |
| Number of anti-HTN medications | 4 (1) | 0 | |
| Beta Blocker (%) | 76.11 | 0 | |
| ACE-I (%) | 64.17 | 0 | |
| ARB (%) | 53.73 | 0 | |
| CCB (%) | 68.65 | 0 | |
| Diuretic (%) | 92.53 | 0 | |
| Other (%) | 40.29 | 0 | |
| BUN (mg/dl) | 13.8 (6) | 11.9 (3.7) | NS |
| Creatinine (mg/dl) | 1 (0.3) | 1 (0.2) | NS |
| Weight (lbs) | 208.4 (45.7) | 173.9 (43.1) | <0.001 |
| BMI (kg/m2) | 31.9 (5.8) | 26.3 (6) | <0.001 |
| BSA (m2) | 2.03 (0.27) | 1.92 (0.24) | 0.024 |
Significant P-value <0.05; NS= not significant